The Food and Drug Administration (FDA or Agency) is withdrawing approval of 24 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Document
GlaxoSmithKline, LLC, et al.; Withdrawal of Approval of 24 Abbreviated New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 24 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Ag...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 49102
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“GlaxoSmithKline, LLC, et al.; Withdrawal of Approval of 24 Abbreviated New Drug Applications,” thefederalregister.org (September 28, 2018), https://thefederalregister.org/documents/2018-21199/glaxosmithkline-llc-et-al-withdrawal-of-approval-of-24-abbreviated-new-drug-applications.